logo-loader
RNS
SkinBioTherapeutics PLC

SkinBioTherapeutics - Issue of Equity and Total Voting Rights

RNS Number : 4968P
SkinBioTherapeutics PLC
20 January 2026
 

A blue text on a white background Description automatically generated

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Issue of Equity and Total Voting Rights

 

20 January 2026 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science business focused on skin health, announces that it has issued, conditional on admission, 129,736 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), pursuant to the share options agreement entered into by the Company and a previous employee upon IPO.

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in issue and application has been made for the new Ordinary Shares to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). Admission is expected to occur, and dealings in the new Ordinary Shares commence, at 8:00 a.m. on 22 January 2026.

 

Total Voting Rights

 

Following Admission, the Company will have 258,779,463 Ordinary Shares in issue. This figure of 258,779,463 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-   

For more information please contact:

SkinBioTherapeutics plc
Stuart J. Ashman, CEO
Emily Bertram, CFO

+44 (0) 191 495 7325

 

Singer Capital Markets (Nominated Adviser & Broker)
Philip Davies
James Todd
Patrick Weaver

+44 (0) 020 7496 3000

 

Vigo Consulting (financial press)
Melanie Toyne-Sewell
Rozi Morris

 

+44 (0) 20 7390 0230

SkinBio@vigoconsulting.com

 

Notes to Editors

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester.

The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix®) and food supplements that harness the gut-skin axis (AxisBiotix™). The cosmetic pillar has a partnership with Croda plc where SkinBiotix® is being used as an active skin ingredient with the Croda trade name, Zenakine™. The AxisBiotix™ pillar has a range of products targeting the symptoms of inflammatory skin conditions, being sold directly and via Amazon, and on the High Street in selected Superdrug Stores plc stores.

The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skincare and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products. 

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEGPUCGGUPQGMB
NO INVESTMENT ADVICE

Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.

It is important for you to know that:

(a) none of the Content is, or is intended to be, general or personal advice

(b) the principal purpose of the Content is to provide factual information only and to comment on news;

(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;

(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and

(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.

The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.

In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read